Advertisement

Topics

Frontline Cabozantinib Approved in Europe for Advanced RCC

17:35 EDT 17 May 2018 | OncLive

The European Commission has approved cabozantinib (Cabometyx) for previously untreated patients with intermediate- or poor-risk advanced renal cell carcinoma.

Original Article: Frontline Cabozantinib Approved in Europe for Advanced RCC

NEXT ARTICLE

More From BioPortfolio on "Frontline Cabozantinib Approved in Europe for Advanced RCC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...